Date: 2017-10-03
Type of information: Plant acquisition
Compound: clinical-stage mammalian manufacturing site in Hayward (USA - CA)
Company: Lonza (Switzerland) Shire (UK - USA)
Therapeutic area: Technology - Services
Type agreement: plant acquisition
Action mechanism:
Disease:
Details:
- • On October 3, 2017, Lonza announced that the group is acquiring a clinical-stage mammalian manufacturing site in Hayward CA (USA) from Shire. The 58,000-square-foot (approximately 5,388-squaremeter) site has been operating as a multiproduct cGMP facility since 1990. Assets include 1,000L and 2,000L single-use bioreactors and associated downstream capabilities. Currently the site employs more than 100 personnel, all of whom will have the opportunity to continue in their role with Lonza.
In response to Lonza’s Pharma&Biotech customers’ increasing demand for clinical-stage manufacturing capacity, the acquisition of the site will provide additional cGMP capacity and will supplement Lonza's existing assets in Slough (UK). Lonza customer batches will be initiated in 2018.
Financial terms:
- Financial details of the deal were not disclosed.
Latest news:
Is general: Yes
